Innovative vaccines for a healthier world

Isconova AB is a leading international vaccine adjuvant company. With its vast knowledge of vaccine systems Isconova develops vaccines together with partners in the human and veterinary markets. Isconovas human vaccine adjuvant Matrix-M™ has been evaluated in two clinical phase I trials where is elicited strong humoral and cellular immune responses with a very good safety profile.

Partners
   

 

Launched vaccines with Isconova's adjuvant

Rabifel® - Rabies vaccine for cats, 2012, VetBioChem

Rabix® - Rabies vaccine for dogs, 2012, VetBioChem

Canvac CCi® - Bordetella bronchiseptica, 2007, Pfizer

Equilis® Prequenza - Equine influenza, 2006, Intervet, now MSD animal health

Pestigard® - Bovine BVDV, 2003, Pfizer

Equity® - Equine LHRH, 2002, Pfizer

Equip® - Equine influenza, 1993, Schering-Plough. From Oct. 2008, Pfizer

 

Human vaccines pipeline

From early stage development to clinical phase studies Matrix-M™ shows excellent results.

To the pipeline>>

 

Annual Report 2012

Go to Annual Report 2012 >>


EXCLUSIVE INTERVIEW WITH DR. MICHAEL S. DIAMOND

Dr. Michael S. Diamond, a world-wide recognized West Nile Virus expert from Washington University in St. Louis, USA attended the West Nile Consortium meeting in Uppsala. Isconova had the opportunity to ask him a couple of questions. See the interesting interview here.

To the interview >>